Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lyell Immunopharma Inc (LYEL)

Lyell Immunopharma Inc (LYEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Lyell Immunopharma Inc 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 USA

www.lyell.com Employees: 300 P: 650-695-0677

Sector:

Medical

Description:

Lyell Immunopharma Inc. is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell Immunopharma Inc. is based in SOUTH SAN FRANCISCO, Calif.

Key Statistics

Overview:

Market Capitalization, $K 505,607
Enterprise Value, $K 400,007
Shares Outstanding, K 21,244
Float, K 16,507
% Float 77.70%
Short Interest, K 592
Short Float 2.79%
Days to Cover 6.28
Short Volume Ratio 0.57
% of Insider Shareholders 22.30%
% of Institutional Shareholders 66.05%

Financials:

Annual Sales, $ 60 K
Annual Net Income, $ -342,990 K
Last Quarter Sales, $ 20 K
Last Quarter Net Income, $ -38,850 K
EBIT, $ -255,720 K
EBITDA, $ -250,770 K

Growth:

1-Year Return 57.50%
3-Year Return -40.20%
5-Year Return 0.00%
5-Year Revenue Growth -90.91%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -2.13 on 11/12/25
Next Earnings Date 03/10/26 [--]
Earnings Per Share ttm -23.02
EPS Growth vs. Prev Qtr 26.30%
EPS Growth vs. Prev Year 37.35%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 06/02/25

LYEL Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -96.68%
Return-on-Assets % -76.00%
Profit Margin % -571,650.00%
Debt/Equity 0.00
Price/Sales 8,938.66
Price/Cash Flow N/A
Price/Book 1.36
Book Value/Share 17.13
Interest Coverage -2.43
60-Month Beta -0.14
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar